Evidence map›Paper›PMID 38009668›Full record

ReviewCell cycle (Georgetown, Tex.)2023

Role of non-coding RNAs as new therapeutic targets in regulating the EMT and apoptosis in metastatic gastric and colorectal cancers.

Nasim Ebrahimi, Ali Hakimzadeh, Farima Bozorgmand, Sepehr Speed, Mahdokht Sadat Manavi, Roya Khorram, Kobra Farahani, Fatemeh Rezaei-Tazangi, Atena Mansouri, Michael R Hamblin and 1 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell cycle (Georgetown, Tex.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 11 institutions in 5 countries.

Nasim EbrahimiGenetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran.
Ali HakimzadehDepartment of Medical Biotechnologies, University of Siena, Tuscany, Italy.
Farima BozorgmandDepartment of Medical Nanotechnology, Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran.
Sepehr SpeedMedical Campus, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Mahdokht Sadat ManaviOtolaryngology Department, Tehran University of Medical Science, Tehran, Iran.
Roya KhorramBone and Joint Diseases Research Center, Department of Orthopedic Surgery, Shiraz University of Medical Sciences, Shiraz, Iran.
Kobra FarahaniDepartment of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran.
Fatemeh Rezaei-TazangiDepartment of Anatomy, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
Atena MansouriDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Michael R HamblinLaser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, South Africa.
Amir Reza ArefXsphera Biosciences, Translational Medicine group, Boston, MA, USA.
Dana-Farber Cancer Institute · USFasa University of Medical Sciences · IRIran University of Medical Sciences · IRIslamic Azad University, Damghan Branch · IRIslamic Azad University Pharmaceutical Sciences Branch · IRIslamic Azad University, Science and Research Branch · IRShiraz University of Medical Sciences · IRUniversity of Isfahan · IRUniversity of Siena · ITUniversity of Tehran · IRXi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) and gastric cancer (GC), are the two most common cancers of the gastrointestinal tract, and are serious health concerns worldwide. The discovery of more effective biomarkers for early diagnosis, and improved patient prognosis is important. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), can regulate cellular processes such as apoptosis and the epithelial-mesenchymal transition (EMT) leading to progression and resistance of GC and CRC tumors. Moreover these pathways (apoptosis and EMT) may serve as therapeutic targets, to prevent metastasis, and to overcome drug resistance. A subgroup of ncRNAs is common to both GC and CRC tumors, suggesting that they might be used as biomarkers or therapeutic targets. In this review, we highlight some ncRNAs that can regulate EMT and apoptosis as two opposite mechanisms in cancer progression and metastasis in GC and CRC. A better understanding of the biological role of ncRNAs could open up new avenues for the development of personalized treatment plans for GC and CRC patients.

Indexed as

Colorectal NeoplasmsMicroRNAsRNA, Long NoncodingStomach NeoplasmsApoptosisBiomarkersEpithelial-Mesenchymal TransitionHumansRNA, UntranslatedBiomarkersMicroRNAsRNA, Long NoncodingRNA, UntranslatedApoptosischemoresistanceepithelial-mesenchymal transitiongastrointestinal cancerpersonalized therapy

Identifiers

PMID38009668
PMCPMC10730205
OpenAlexW4389048417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.